Comera Life Sciences Holdings Inc. is a biotechnology company focused on transforming the way biologic medicines are delivered to patients. Leveraging expertise in formulation science, the company is dedicated to converting essential intravenous (IV) biologic therapies into subcutaneous (SQ) forms. This innovation is designed to make treatments more accessible, allowing patients greater autonomy through self-injectable options and reducing dependency on healthcare institutions. Comera Life Sciences’ proprietary SQore platform underpins this approach, aiming to improve the convenience and quality of care for individuals with chronic conditions. The company's most advanced pipeline candidate, CLS-001, is a subcutaneous version of vedolizumab for the treatment of inflammatory bowel diseases, such as Crohn’s disease and ulcerative colitis. Founded in 2014 and based in Woburn, Massachusetts, Comera Life Sciences is part of the healthcare sector and contributes to the evolving landscape of patient-centric biopharmaceuticals by focusing on novel drug delivery solutions.